Evidence map›Paper›PMID 41162355›Full record

ArticleNature communications2025

BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.

Kathy Situ, Haohui Duan, Stephen K Godin, Joshua Yang, Gabrielle Q McCloskey, Basim Naeem, Margaret K Gillis, Muhammad H Zeb, Silvi Salhotra, Pratha Rawal and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. STING causes replication stress and nascent DNA degradation via SAMHD1.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Kathy Situ *Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Haohui Duan *Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Stephen K GodinCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Joshua YangCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Gabrielle Q McCloskeyDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Basim NaeemDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Margaret K GillisDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Muhammad H ZebDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.ORCID http://orcid.org/0009-0002-5598-6930
Silvi SalhotraDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Pratha RawalDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Nisha PatelDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Salome K MouliereDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA.
Jie ChenThe Center of Statistical Computing, University of Massachusetts Boston, Boston, MA, USA.
Angéla BékésiDepartment of Applied Biotechnology and Food Sciences, Faculty of Chemical Technology and Biotechnology, BME Budapest University of Technology and Economics, Műegyetem Rkp. 3, Budapest, Hungary.ORCID http://orcid.org/0000-0003-2294-3002
Hajnalka L PálinkásDepartment of Applied Biotechnology and Food Sciences, Faculty of Chemical Technology and Biotechnology, BME Budapest University of Technology and Economics, Műegyetem Rkp. 3, Budapest, Hungary.
Subramanian VenkatesanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6454-8508
Abby M GreenDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-6436-2217
Nicolai J BirkbakDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-1613-9587
Beáta G VértessyDepartment of Applied Biotechnology and Food Sciences, Faculty of Chemical Technology and Biotechnology, BME Budapest University of Technology and Economics, Műegyetem Rkp. 3, Budapest, Hungary.ORCID http://orcid.org/0000-0002-1288-2982
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4299-3018
Shailja PathaniaCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA. Shailja.pathania@umb.edu.ORCID http://orcid.org/0000-0001-8974-6420

Funding

Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 DeficiencyR01CA273696 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI PATHANIA, SHAILJA · 2022 to 2025
$1.8M
Maintenance of genome integrity by the SMC5/6 complex during deaminase-mediated mutagenesisR01GM153923 · NIGMS · WASHINGTON UNIVERSITY · PI ABBY Margaret GREEN · 2025 to 2026
$594k
Base Excision Repair Deficiency as a Risk Modifier in BRCA2 Associated CancerR15CA235436 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI PATHANIA, SHAILJA · 2019 to 2019
$456k
NCI NIH HHS R01 CA273696NCI NIH HHS R15 CA235436NIGMS NIH HHS R01 GM153923United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) BC160079U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA273696U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R15CA235436
6 · The paper itself

Abstract

BRCA2 plays a critical role in stabilizing stalled replication forks, yet critical gaps remain in understanding how BRCA2 deficiency triggers fork collapse and drives genomic instability. Here, we identify cytidine deaminase APOBEC3B as a key driver of this process. Using a unique uracil-in-DNA probe, we show that BRCA2 loss promotes APOBEC3B-mediated uracil accumulation in single-stranded DNA (U-ssDNA) at stalled forks. These lesions when processed by UNG2 and APE1, trigger fork collapse and release ssDNA fragments into the cytoplasm, activating NF-κB signaling. This in turn upregulates APOBEC3B expression, establishing a self-reinforcing loop that amplifies cytidine deamination at stalled forks and exacerbates genomic instability. Depletion of APOBEC3B, UNG2, or APE1 rescues these defects. Notably, BRCA1-deficient cells do not accumulate U-ssDNA or induce APOBEC3B under replication stress, highlighting a BRCA2-specific vulnerability. Clinically, low APE1 expression correlates with poor survival in patients with BRCA2-mutant tumors, with high APOBEC3 levels further worsening outcomes. Together, our findings establish that replication stress, whether intrinsic or therapy induced, triggers APOBEC3B overexpression and potentially activates an APOBEC3B-driven mutagenic loop in BRCA2-deficient cells. These results position APOBEC3B, UNG2 and APE1 as critical regulators of BRCA2-mutant tumor evolution and therapy resistance.

Indexed as

BRCA2 ProteinCytidine DeaminaseDNA ReplicationGenomic InstabilityMinor Histocompatibility AntigensAPOBEC DeaminasesCell Line, TumorDNA-(Apurinic or Apyrimidinic Site) LyaseDNA, Single-StrandedFemaleHumansAPOBEC3B protein, humanAPOBEC3 proteins, humanAPOBEC DeaminasesBRCA2 ProteinBRCA2 protein, humanCytidine DeaminaseDNA-(Apurinic or Apyrimidinic Site) LyaseDNA, Single-StrandedMinor Histocompatibility Antigens

Identifiers

PMID41162355
PMCPMC12572151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.